Your browser is no longer supported. Please, upgrade your browser.
Bicycle Therapeutics plc
Index- P/E- EPS (ttm)-2.07 Insider Own29.90% Shs Outstand19.43M Perf Week39.96%
Market Cap568.83M Forward P/E- EPS next Y-2.82 Insider Trans-0.98% Shs Float4.33M Perf Month47.94%
Income-38.00M PEG- EPS next Q-0.47 Inst Own42.90% Short Float7.68% Perf Quarter49.34%
Sales11.80M P/S48.21 EPS this Y-124.50% Inst Trans1.96% Short Ratio3.82 Perf Half Y52.40%
Book/sh5.64 P/B5.02 EPS next Y-24.40% ROA-28.80% Target Price27.75 Perf Year146.52%
Cash/sh7.45 P/C3.80 EPS next 5Y- ROE-42.70% 52W Range10.26 - 31.09 Perf YTD57.66%
Dividend- P/FCF- EPS past 5Y- ROI-27.90% 52W High-8.97% Beta-
Dividend %- Quick Ratio9.60 Sales past 5Y- Gross Margin- 52W Low175.83% ATR1.89
Employees72 Current Ratio9.60 Sales Q/Q533.30% Oper. Margin- RSI (14)74.97 Volatility12.50% 6.92%
OptionableNo Debt/Eq0.13 EPS Q/Q1.50% Profit Margin- Rel Volume1.72 Prev Close29.96
ShortableYes LT Debt/Eq0.13 EarningsNov 05 Payout- Avg Volume87.14K Price28.30
Recom1.60 SMA2037.05% SMA5041.04% SMA20059.51% Volume149,694 Change-5.54%
Oct-12-20Initiated Cantor Fitzgerald Overweight $30
Jun-12-20Initiated Oppenheimer Outperform
Apr-17-20Initiated H.C. Wainwright Buy $25
Nov-14-19Initiated ROTH Capital Buy $17
Sep-11-19Upgrade Goldman Neutral → Buy $14
Jun-17-19Initiated Piper Jaffray Overweight $20
Jun-17-19Initiated Jefferies Buy $22
Jun-17-19Initiated Goldman Neutral $14
Jun-17-19Initiated Canaccord Genuity Buy $22
Jan-14-21 07:00AM  
Jan-06-21 11:58PM  
Dec-09-20 01:32PM  
Nov-24-20 06:59AM  
Nov-20-20 04:05PM  
Nov-12-20 04:01PM  
Nov-09-20 06:59AM  
Nov-08-20 07:17AM  
Nov-05-20 06:59AM  
Oct-21-20 06:59AM  
Oct-14-20 05:08PM  
Oct-01-20 08:06AM  
Sep-19-20 08:03AM  
Sep-18-20 07:30AM  
Sep-14-20 06:59AM  
Sep-10-20 04:05PM  
Sep-03-20 06:59AM  
Sep-02-20 06:59AM  
Sep-01-20 06:59AM  
Aug-06-20 08:03AM  
Aug-05-20 04:05PM  
Jun-24-20 08:37AM  
Jun-23-20 06:59AM  
Jun-22-20 06:59AM  
Jun-13-20 07:56AM  
Jun-12-20 06:46PM  
May-27-20 06:59AM  
May-15-20 06:59AM  
May-13-20 05:09PM  
May-12-20 06:59AM  
May-08-20 09:32AM  
May-07-20 06:59AM  
May-06-20 06:59AM  
May-05-20 06:59AM  
Apr-23-20 06:59AM  
Apr-08-20 07:16AM  
Apr-07-20 06:59AM  
Apr-06-20 06:59AM  
Mar-31-20 07:22AM  
Mar-30-20 11:30AM  
Mar-17-20 06:45AM  
Mar-16-20 08:38AM  
Mar-13-20 12:00PM  
Mar-10-20 06:59AM  
Feb-25-20 06:59AM  
Jan-07-20 07:00AM  
Dec-22-19 06:09PM  
Nov-26-19 07:00AM  
Nov-14-19 07:00AM  
Nov-13-19 07:00AM  
Nov-07-19 07:00AM  
Nov-05-19 08:14AM  
Oct-31-19 07:00AM  
Oct-29-19 07:00AM  
Oct-22-19 03:00AM  
Oct-16-19 04:33PM  
Sep-28-19 06:00AM  
Sep-24-19 07:00AM  
Sep-19-19 09:23AM  
Aug-08-19 07:00AM  
Jul-24-19 08:00AM  
Jul-01-19 07:46AM  
May-23-19 01:09PM  
May-22-19 09:49PM  
May-21-19 04:45PM  
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. Bicycle Therapeutics plc has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lee KevinChief Executive OfficerJan 15Sale27.015,000135,050265,085Jan 15 04:40 PM
Kalowski LeePresident and CFOJan 14Option Exercise1.6010,00016,00010,000Jan 15 04:44 PM
Kalowski LeePresident and CFOJan 14Sale25.0010,000250,0000Jan 15 04:44 PM
Lee KevinChief Executive OfficerJan 14Sale25.005,000125,000270,085Jan 15 04:40 PM
Kalowski LeePresident and CFODec 01Option Exercise1.567,50011,7007,500Dec 03 08:53 PM
Kalowski LeePresident and CFODec 01Sale22.507,500168,7500Dec 03 08:53 PM
Kalowski LeePresident and CFONov 27Option Exercise1.56530827530Nov 30 04:42 PM
Kalowski LeePresident and CFONov 27Sale20.0053010,6000Nov 30 04:42 PM
Kalowski LeePresident and CFONov 25Option Exercise1.569,78115,2589,781Nov 25 08:31 PM
Kalowski LeePresident and CFONov 25Sale20.079,781196,3050Nov 25 08:31 PM
Kalowski LeePresident and CFONov 23Option Exercise1.5617,18926,81517,189Nov 25 08:31 PM
Kalowski LeePresident and CFONov 23Sale19.8317,189340,8050Nov 25 08:31 PM
GLAXOSMITHKLINE PLC10% OwnerJul 15Sale19.403,14761,0451,910,531Sep 18 12:04 PM
GLAXOSMITHKLINE PLC10% OwnerJul 14Sale19.271,59730,7811,913,678Sep 18 12:04 PM